According to WiseGuy Reports, the Diosmin API Market was valued at USD 744.1 million in 2024 and reached USD 776.9 million in 2025. The market is projected to reach USD 1,200.0 million by 2035, registering a CAGR of 4.4% during the forecast period from 2026 to 2035. Increasing prevalence of chronic venous conditions, rising demand for diosmin-based pharmaceutical formulations, growing interest in dietary supplements, increasing health awareness, and advancements in extraction and manufacturing technologies are supporting market expansion. Key companies profiled include Zhejiang Haizhen Pharmaceutical, Cipla, Hunan Zhongke Pharmaceutical, Lanzhou Pharmaceutical, Chongqing Kewang Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Hikma Pharmaceuticals, Stada Arzneimittel AG, Kusum Healthcare, and Vitae Naturals.
Market Overview
Diosmin is a flavonoid-based active pharmaceutical ingredient used primarily in products associated with vascular health and venous circulation. Its established role in pharmaceutical formulations has created consistent demand from manufacturers producing tablets, capsules, powders, and liquid products.
The market extends beyond conventional pharmaceutical applications. Diosmin is also being incorporated into nutraceutical and selected cosmetic formulations as consumers and manufacturers show greater interest in plant-derived active ingredients.
Demand is influenced by healthcare needs, formulation development, regulatory requirements, and the availability of reliable pharmaceutical-grade raw materials. API manufacturers therefore compete on quality, consistency, production capabilities, regulatory compliance, and supply reliability.
Market Size Reached in 2025
The market reached USD 776.9 million in 2025, compared with USD 744.1 million in 2024. The increase reflects continued demand from pharmaceutical manufacturers and growing interest in products targeting venous health.
Pharmaceutical applications remain central to the market because diosmin is incorporated into formulations designed for vascular and circulatory health. Hospitals, clinics, and homecare settings contribute to downstream demand through the use of related products.
The expansion of online retail and specialty distribution channels is also improving consumer access to nutraceutical and health-oriented formulations containing diosmin.
Expected Market Size by 2035
The market is expected to reach USD 1.2 billion by 2035. Increasing awareness of chronic venous conditions and the need for supportive therapies are expected to sustain demand for diosmin APIs.
The nutraceutical segment provides an additional growth avenue. Consumers are increasingly seeking dietary products containing plant-derived ingredients, creating opportunities for manufacturers to develop diosmin-based supplements.
Cosmetic and food-additive applications may provide further diversification, particularly as formulation companies explore the functional properties of botanical compounds.
Market CAGR
The market is projected to grow at a CAGR of 4.4% from 2026 to 2035. The steady pace of expansion reflects a combination of pharmaceutical demand, increasing supplement consumption, and advances in API production.
Improved extraction and purification technologies can help manufacturers achieve greater consistency and support the production of higher-quality active ingredients.
Key Growth Drivers
The prevalence of chronic venous conditions is an important factor supporting demand. As healthcare systems and consumers place greater attention on vascular health, demand for products containing established active ingredients can increase.
Dietary supplement consumption is another contributor. Growing health consciousness has encouraged consumers to consider nutraceutical products containing naturally derived compounds.
Advancements in extraction technologies are also improving production capabilities. More efficient processes can support consistent quality, scalability, and cost management.
The pharmaceutical industry's continued development of specialized formulations provides another source of demand for high-quality diosmin APIs.
Emerging Market Trends
A significant trend is the increasing integration of botanical active ingredients into nutraceutical products. Diosmin's established association with vascular health provides opportunities for supplement manufacturers seeking recognizable functional ingredients.
Manufacturers are also focusing on API purity and consistency. Pharmaceutical customers require reliable raw materials that meet defined quality specifications and regulatory standards.
Digital distribution is changing the downstream market as well. Online retail provides consumers with broader access to supplements and health products, supporting demand beyond traditional pharmacy channels.
Regional production capabilities are also evolving as pharmaceutical companies seek reliable supply chains and diversified sourcing arrangements.
Competitive Landscape
The competitive landscape consists primarily of pharmaceutical manufacturers, API producers, specialty ingredient suppliers, and companies serving nutraceutical applications. Competition is influenced by product quality, regulatory compliance, manufacturing capacity, pricing, technical expertise, and supply reliability.
Zhejiang Haizhen Pharmaceutical, Cipla, Hunan Zhongke Pharmaceutical, Lanzhou Pharmaceutical, Chongqing Kewang Pharmaceutical, Jiangsu Lianhuan Pharmaceutical, Taj Pharmaceuticals, Hikma Pharmaceuticals, Stada Arzneimittel AG, Kusum Healthcare, Hubei Xunda Pharmaceutical, Pharma Synthese, Hubei Shijia Pharmaceutical, Vitae Naturals, Changsha Boli Pharmaceutical, and HPLC Standards are among the companies profiled.
Market participants are expected to concentrate on manufacturing efficiency, quality assurance, regulatory capabilities, and expanded applications across pharmaceutical and nutraceutical formulations. Companies that can provide consistent APIs and dependable supply are likely to remain well positioned as demand increases through 2035.